HC Wainwright restated their buy rating on shares of Lion Biotechnologies, Inc. (NASDAQ:IOVA) in a research report report published on Monday. The brokerage currently has a $16.00 price objective on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the stock. Chardan Capital reissued a buy rating on shares of Lion Biotechnologies in a report on Thursday, September 7th. Oppenheimer Holdings, Inc. reissued a buy rating and issued a $13.00 price target on shares of Lion Biotechnologies in a report on Monday. B. Riley reissued a buy rating and issued a $18.00 price target on shares of Lion Biotechnologies in a report on Monday. Zacks Investment Research raised shares of Lion Biotechnologies from a hold rating to a buy rating and set a $7.00 price target on the stock in a report on Tuesday, July 18th. Finally, Cowen and Company reissued a buy rating on shares of Lion Biotechnologies in a report on Wednesday, August 16th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Lion Biotechnologies presently has an average rating of Buy and a consensus price target of $14.53.

Lion Biotechnologies (NASDAQ IOVA) traded down $0.40 during trading on Monday, reaching $7.65. 392,400 shares of the company were exchanged, compared to its average volume of 363,789. Lion Biotechnologies has a twelve month low of $4.45 and a twelve month high of $8.60.

Lion Biotechnologies (NASDAQ:IOVA) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). analysts forecast that Lion Biotechnologies will post -1.37 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Lion Biotechnologies, Inc. (IOVA) Given “Buy” Rating at HC Wainwright” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/lion-biotechnologies-inc-iova-given-buy-rating-at-hc-wainwright/1703106.html.

Several institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. boosted its stake in shares of Lion Biotechnologies by 6.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 222,015 shares of the biotechnology company’s stock valued at $1,721,000 after purchasing an additional 12,883 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Lion Biotechnologies by 44.2% in the 3rd quarter. Wells Fargo & Company MN now owns 103,528 shares of the biotechnology company’s stock valued at $801,000 after purchasing an additional 31,724 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Lion Biotechnologies in the 3rd quarter valued at $307,000. JPMorgan Chase & Co. boosted its stake in shares of Lion Biotechnologies by 63.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,779,700 shares of the biotechnology company’s stock valued at $14,059,000 after purchasing an additional 690,527 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Lion Biotechnologies in the 3rd quarter valued at $133,000. 65.76% of the stock is owned by institutional investors.

About Lion Biotechnologies

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.